About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2025 with the Securities and Exchange Commission (SEC) on Friday, November 14, 2025. ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 1320 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2025 Commission File Number: 001-36081 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) of incorporation or organization) Delaware 76-0674577 (State or other jurisdiction) (IRS Employer Identification No.) 1 Controls Drive Shelton, Connecticut 06484 (Address ...

Core Viewpoint - NanoViricides, Inc. is a clinical stage company focused on developing broad-spectrum antiviral drugs that are designed to be effective against viruses without the risk of escape [1] Group 1: Event Information - NanoViricides will present at the Pharma Partnering Summit 2025 on November 14, 2025, from 11:25 am to 11:45 am ET [1] - The event will take place at the Hilton Boston Logan Airport in Boston, MA [1]

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Core Points - NanoViricides, Inc. has completed a securities purchase agreement with a healthcare institutional investor [1] - The agreement involves the purchase of 3,571,429 shares of common stock at a price of $1.68 per share [1] - The gross proceeds from this offering amount to approximately $6 million before expenses [1]

Group 1 - Proactive specializes in providing fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's news team delivers insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and improve content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Points - NanoViricides, Inc. has entered into a securities purchase agreement with a healthcare institutional investor for the sale of 3,571,429 shares of common stock at a price of $1.68 per share [1] - The gross proceeds from this registered direct offering are expected to be approximately $6 million, before deducting placement agent commissions and other offering expenses [1] Company Summary - The offering involves the sale of common stock or common stock equivalents [1] - The transaction is structured as a registered direct offering, indicating a streamlined process for raising capital [1]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] - Proactive specializes in medium and small-cap markets while also keeping the community updated on blue-chip companies, commodities, and broader investment stories [2][3] Group 2 - The team delivers news and insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] - Proactive adopts technology to enhance workflows and improve content production [4] - Automation and software tools, including generative AI, are utilized, but all content is edited and authored by humans [5]

Core Viewpoint - NanoViricides, Inc. has received approval from the regulatory agency ACOREP in the Democratic Republic of Congo to start Phase II clinical trials for NV-387, a broad-spectrum antiviral drug aimed at treating MPox disease caused by hMPXV infection [1][2]. Regulatory Approval - The Phase II clinical trial for NV-387 is cleared to proceed, contingent upon the filing of certain documents [2]. - The approval marks a significant milestone in the regulatory development of NV-387, as stated by the company's President and Executive Chairman, Anil R. Diwan [2]. Current Treatment Landscape - There are currently no effective drugs available for treating hMPXV infections that cause MPox disease. A clinical trial for tecovirimat (TPOXX®) failed to show effectiveness over placebo [3]. - Another drug, brincidofovir (TEMBEXA®), is undergoing a clinical trial called "MOSA," but its current status is unknown [3]. MPox Disease Context - MPox Clade II has become endemic in the USA, primarily affecting a limited population of men who have sex with men (MSM) due to transmission during sexual activity [4]. - Recent cases of MPox Clade I in California suggest potential community spread of the virus [5]. NV-387 Drug Profile - NV-387 is designed to mimic human cells, allowing it to trap and destroy viruses, targeting over 90-95% of human pathogenic viruses [6]. - The drug has shown high effectiveness in animal models against various viral infections, including influenza, RSV, and coronaviruses, surpassing existing treatments [10][11]. - NV-387 has demonstrated strong antiviral activity against orthopoxviruses, indicating potential effectiveness against MPox and Smallpox [12]. Development and Future Prospects - The company is compiling required documentation for the Clinical Trial Application, which will be submitted to ACOREP for patient recruitment approval [7][8]. - NV-387 is positioned as a revolutionary treatment for viral diseases, with the potential to address the limitations of current antiviral therapies [15][16]. Company Overview - NanoViricides, Inc. is a clinical-stage company focused on developing nanomaterials for antiviral therapy, with a lead drug candidate NV-387 targeting multiple viral infections, including MPox [17][20]. - The company has a licensing agreement with TheraCour Pharma for the development of antiviral drugs, holding exclusive rights to several technologies [19][22].